# PRODUCT INFORMATION



## TM5441

Item No. 22965

CAS Registry No.: 1190221-43-2

5-chloro-2-[[2-[2-[[3-(3-furanyl)phenyl]amino]-Formal Name:


2-oxoethoxylacetyllaminol-benzoic acid

MF: C<sub>21</sub>H<sub>17</sub>CIN<sub>2</sub>O<sub>6</sub>

FW: 428.8 **Purity:** ≥98%  $\lambda_{max}$ : 226 nm A crystalline solid UV/Vis.: Supplied as:

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



### **Laboratory Procedures**

TM5441 is supplied as a crystalline solid. A stock solution may be made by dissolving the TM5441 in the solvent of choice. TM5441 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of TM5441 in these solvents is approximately 20 and 33 mg/ml, respectively.

TM5441 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, TM5441 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. TM5441 has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor 1 (PAI-1), a serine-protease inhibitor involved in thrombosis. 1.2 It decreases survival of HT1080, HCT116, Daoy, MDA-MB-231, and Jurkat cancer cells with IC<sub>50</sub> values ranging from 13.9 to 51.1  $\mu$ M.<sup>1</sup> TM5441 inhibits branching of human umbilical vein endothelial cells (HUVECs) in a vasculature assay in vitro when used at a concentration of 50 μM but does not affect HUVEC survival or apoptosis. It also disrupts tumor vasculature in HT1080 and HCT116 mouse xenograft models when used at a dose of 20 mg/kg per day. TM5441 prevents hypertension and cardiac hypertrophy and reduces periaortic fibrosis induced by L-NAME (Item No. 80210).<sup>2</sup> It protects against high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in mice when administered concurrently with a high-fat diet or after glucose tolerance has developed.<sup>3</sup> TM5441 also increases median lifespan by 4-fold and reduces signs of senescence in Klotho-deficient mice, a mouse model of aging. 4

#### References

- 1. Placencio, V.R., Ichimura, A., Miyata, T., et al. Small molecule inhibitors of plasminogen activator inhibitor-1 elicit anti-tumorigenic and anti-angiogenic activity. PLoS One 10(7), e0133786 (2015).
- 2. Boe, A.E., Eren, M., Murphy, S.B., et al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation 128(21), 2318-2324 (2013).
- 3. Lee, S.M., Dorotea, D., Jung, I., et al. TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease. Oncotarget 8(52), 89746-89760 (2017).
- Eren, M., Boe, A.E., Murphy, S.B., et al. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc. Natl. Acad. Sci. U.S.A. 111(19), 7090-7095 (2014).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/12/2022

### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM